|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 9 (November 1), 1998:
pp. 3152-3162
Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in
Diffuse Large B-Cell Lymphoma
M.H.H. Kramer,
J. Hermans,
E. Wijburg,
K. Philippo,
E. Geelen,
J.H.J.M. van Krieken,
D. de Jong,
E. Maartense,
E. Schuuring, and
P.M. Kluin
From the Departments of Pathology and Medical Statistics, Leiden
University Medical Center, Leiden; Department of Pathology, The
Netherlands Cancer Institute, Amsterdam; Department of Internal
Medicine, Reinier de Graaf Gasthuis, Delft; and the Comprehensive
Cancer Center West, Leiden, The Netherlands.
Diffuse large B-cell lymphoma (DLCL) is characterized by a marked
degree of morphologic and clinical heterogeneity. We studied 156 patients with de novo DLCL for rearrangements of the BCL2, BCL6, and
MYC oncogenes by Southern blot analysis and BCL2 protein expression. We
related these data to the primary site of presentation, disease stage,
and other clinical risk factors. Structural alterations of BCL2, BCL6,
and MYC were detected in 25 of 156, 36 of 116, and 10 of 151 patients,
respectively. Three cases showed a combination of BCL2 and BCL6
rearrangements, and two cases had a combination of BCL6 and MYC
rearrangements. BCL2 rearrangement was found more often in extensive
(39%) and primary nodal (17%) lymphomas than in extranodal cases
(4%) (P = .003). BCL2 rearrangement was present in none of
40 patients with stage I disease, but in 22% of patients with stage II
to IV (P = .006). The presence of BCL2 rearrangements did
not significantly affect overall survival (OS) or disease-free survival
(DFS). In contrast, high BCL2 protein expression adversely affected
both OS (P = .008) and DFS (P = .01). BCL2
protein expression was poorly correlated with BCL2 rearrangement: only
52% of BCL2-rearranged lymphomas and 37% of BCL2-unrearranged cases
had high BCL2 protein expression. Rearrangement of BCL6 was found more
often in patients with extranodal (36%) and extensive (39%)
presentation versus primary nodal disease (28%). No significant
correlation was found with disease stage, lymphadenopathy, or bone
marrow involvement. DFS and OS were not influenced by BCL6
rearrangements. MYC rearrangements were found in 16% of primary
extranodal lymphomas, versus 2% of primary nodal cases
(P = .02). In particular, gastrointestinal (GI) lymphomas
(5 of 18 cases, 28%) were affected by MYC rearrangements. The distinct
biologic behavior of these extranodal lymphomas was reflected by a high
complete remission (CR) rate: 7 of 10 patients with MYC rearrangement
attained complete remission and 6 responders remained alive for more
than 4 years, resulting in a trend for better DFS
(P = .07). These data show the complex nature of molecular events in DLCL, which is a reflection of the morphologic and clinical heterogeneity of these lymphomas. However, thus far, these genetic rearrangements fail as prognostic markers.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Altuwaijri, K.-H. Chuang, K.-P. Lai, J.-J. Lai, H.-Y. Lin, F. M. Young, A. Bottaro, M.-Y. Tsai, W.-P. Zeng, H.-C. Chang, et al.
Susceptibility to Autoimmunity and B Cell Resistance to Apoptosis in Mice Lacking Androgen Receptor in B Cells
Mol. Endocrinol.,
April 1, 2009;
23(4):
444 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bhagavathi and K. Fu
Primary Bone Lymphoma and BCL6
Am J Clin Pathol,
January 1, 2009;
131(1):
144 - 144.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. de Paiva, J. Vassallo, and P. Brousset
The Authors' Reply
Am J Clin Pathol,
January 1, 2009;
131(1):
145 - 146.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, et al.
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Ann. Onc.,
November 1, 2008;
19(11):
1921 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al.
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
October 1, 2008;
26(28):
4587 - 4594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nakamura, H. Ye, C. M. Bacon, A. Goatly, H. Liu, L. Kerr, A. H. Banham, B. Streubel, T. Yao, M. Tsuneyoshi, et al.
Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma
Clin. Cancer Res.,
May 15, 2008;
14(10):
3002 - 3010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Quijano, A. Lopez, A. Rasillo, S. Barrena, M. Luz Sanchez, J. Flores, C. Fernandez, J. M. Sayagues, C. S. Osuna, N. Fernandez, et al.
Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients
Blood,
May 15, 2008;
111(10):
5130 - 5141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dierlamm, E. M. Murga Penas, S. Bentink, S. Wessendorf, H. Berger, M. Hummel, W. Klapper, D. Lenze, A. Rosenwald, E. Haralambieva, et al.
Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma
Haematologica,
May 1, 2008;
93(5):
688 - 696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. G. M. Cillessen, J. C. Reed, K. Welsh, C. Pinilla, R. Houghten, E. Hooijberg, J. Deurhof, K. C. M. Castricum, P. Kortman, C. J. Hess, et al.
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells
Blood,
January 1, 2008;
111(1):
369 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Le Gouill, P. Talmant, C. Touzeau, A. Moreau, R. Garand, N. Juge-Morineau, F. Gaillard, T. Gastinne, N. Milpied, P. Moreau, et al.
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement
Haematologica,
October 1, 2007;
92(10):
1335 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Prakash and S. H Swerdlow
Nodal aggressive B-cell lymphomas: a diagnostic approach
J. Clin. Pathol.,
October 1, 2007;
60(10):
1076 - 1085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
Blood,
June 1, 2007;
109(11):
4930 - 4935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Mohammad, A. S. Goustin, A. Aboukameel, B. Chen, S. Banerjee, G. Wang, Z. Nikolovska-Coleska, S. Wang, and A. Al-Katib
Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1
Clin. Cancer Res.,
April 1, 2007;
13(7):
2226 - 2235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Chen, X.-T. Hu, A. C. Liang, W.-Y. Au, C.-C. So, M. L. Wong, L. Shen, Q. Tao, K.-M. Chu, Y.-L. Kwong, et al.
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma
Blood,
October 1, 2006;
108(7):
2373 - 2383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Sha, M. G. Tadesse, and M. Vannucci
Bayesian variable selection for the analysis of microarray data with censored outcomes
Bioinformatics,
September 15, 2006;
22(18):
2262 - 2268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin
Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 1, 2006;
24(25):
4135 - 4142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Wallace, D. Shen, G. F. Reed, M. Miyanaga, M. Mochizuki, H. N. Sen, S. S. Dahr, R. R. Buggage, R. B. Nussenblatt, and C.-C. Chan
Detection of the bcl-2 t(14;18) Translocation and Proto-Oncogene Expression in Primary Intraocular Lymphoma.
Invest. Ophthalmol. Vis. Sci.,
July 1, 2006;
47(7):
2750 - 2756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hummel, S. Bentink, H. Berger, W. Klapper, S. Wessendorf, T. F.E. Barth, H.-W. Bernd, S. B. Cogliatti, J. Dierlamm, A. C. Feller, et al.
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
N. Engl. J. Med.,
June 8, 2006;
354(23):
2419 - 2430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Dave, K. Fu, G. W. Wright, L. T. Lam, P. Kluin, E.-J. Boerma, T. C. Greiner, D. D. Weisenburger, A. Rosenwald, G. Ott, et al.
Molecular diagnosis of Burkitt's lymphoma.
N. Engl. J. Med.,
June 8, 2006;
354(23):
2431 - 2442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, E. A. Weller, S. J. Horning, M. Krajewska, D. Variakojis, T. M. Habermann, R. I. Fisher, P. J. Kurtin, W. R. Macon, M. Chhanabhai, et al.
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Blood,
June 1, 2006;
107(11):
4207 - 4213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch
Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial
Blood,
May 15, 2006;
107(10):
4047 - 4052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist,
April 1, 2006;
11(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos and D. Morgensztern
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
995 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Iqbal, V. T. Neppalli, G. Wright, B. J. Dave, D. E. Horsman, A. Rosenwald, J. Lynch, C. P. Hans, D. D. Weisenburger, T. C. Greiner, et al.
BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
961 - 968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Margalit, H. Amram, N. Amariglio, A. J. Simon, S. Shaklai, G. Granot, N. Minsky, A. Shimoni, A. Harmelin, D. Givol, et al.
BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma
Blood,
February 15, 2006;
107(4):
1599 - 1607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. De Paepe, R. Achten, G. Verhoef, I. Wlodarska, M. Stul, V. Vanhentenrijk, M. Praet, and C. De Wolf-Peeters
Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas
J. Clin. Oncol.,
October 1, 2005;
23(28):
7060 - 7068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A K H Shia, G-G Gan, S Jairaman, and S-C Peh
High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients
J. Clin. Pathol.,
September 1, 2005;
58(9):
962 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tagawa, M. Suguro, S. Tsuzuki, K. Matsuo, S. Karnan, K. Ohshima, M. Okamoto, Y. Morishima, S. Nakamura, and M. Seto
Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma
Blood,
September 1, 2005;
106(5):
1770 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Vega, A. R. Jazirehi, S. Huerta-Yepez, and B. Bonavida
Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin's Lymphoma Cell Line via Inhibition of NF-{kappa}B Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively
J. Immunol.,
August 15, 2005;
175(4):
2174 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson and M. A. Shipp
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
Blood,
August 15, 2005;
106(4):
1164 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lopez-Guillermo, L. Colomo, M. Jimenez, F. Bosch, N. Villamor, L. Arenillas, A. Muntanola, S. Montoto, E. Gine, D. Colomer, et al.
Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin
J. Clin. Oncol.,
April 20, 2005;
23(12):
2797 - 2804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Monti, K. J. Savage, J. L. Kutok, F. Feuerhake, P. Kurtin, M. Mihm, B. Wu, L. Pasqualucci, D. Neuberg, R. C. T. Aguiar, et al.
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
Blood,
March 1, 2005;
105(5):
1851 - 1861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tagawa, S. Tsuzuki, R. Suzuki, S. Karnan, A. Ota, Y. Kameoka, M. Suguro, K. Matsuo, M. Yamaguchi, M. Okamoto, et al.
Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma: Comparison between CD5-Positive and CD5-Negative Cases
Cancer Res.,
September 1, 2004;
64(17):
5948 - 5955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, D. K. Czerwinski, A. A. Alizadeh, M. A. Wechser, R. Tibshirani, D. Botstein, and R. Levy
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
N. Engl. J. Med.,
April 29, 2004;
350(18):
1828 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Hans, D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie, G. Ott, H. K. Muller-Hermelink, E. Campo, R. M. Braziel, E. S. Jaffe, et al.
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Blood,
January 1, 2004;
103(1):
275 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Akasaka, I. S. Lossos, and R. Levy
BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma
Blood,
August 15, 2003;
102(4):
1443 - 1448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. de Jong, A. M. Glas, L. Boerrigter, M.-C. Hermus, O. Dalesio, E. Willemse, P. M. Nederlof, and M. J. Kersten
Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features
Blood,
July 1, 2003;
102(1):
324 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Barrans, P. A. S. Evans, S. J. M. O'Connor, S. J. Kendall, R. G. Owen, A. P. Haynes, G. J. Morgan, and A. S. Jack
The t(14;18) Is Associated with Germinal Center-derived Diffuse Large B-Cell Lymphoma and Is a Strong Predictor of Outcome
Clin. Cancer Res.,
June 1, 2003;
9(6):
2133 - 2139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mounier, J. Briere, C. Gisselbrecht, J.-F. Emile, P. Lederlin, C. Sebban, F. Berger, A. Bosly, P. Morel, H. Tilly, et al.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
Blood,
June 1, 2003;
101(11):
4279 - 4284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris
Cell cycle deregulation in B-cell lymphomas
Blood,
February 15, 2003;
101(4):
1220 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, A. A. Alizadeh, R. Rajapaksa, R. Tibshirani, and R. Levy
HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma
Blood,
January 15, 2003;
101(2):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. G. Krol, S. le Cessie, S. Snijder, J. C. Kluin-Nelemans, P. M. Kluin, and E. M. Noordijk
Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry
Ann. Onc.,
January 1, 2003;
14(1):
131 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Colomo, A. Lopez-Guillermo, M. Perales, S. Rives, A. Martinez, F. Bosch, D. Colomer, B. Falini, E. Montserrat, and E. Campo
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
Blood,
January 1, 2003;
101(1):
78 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. ten Berge, C. J. L. M. Meijer, D. F. Dukers, J. A. Kummer, B. A. Bladergroen, W. Vos, C. E. Hack, G. J. Ossenkoppele, and J. J. Oudejans
Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma
Blood,
May 29, 2002;
99(12):
4540 - 4546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Z. Huang, W. G. Sanger, T. C. Greiner, L. M. Staudt, D. D. Weisenburger, D. L. Pickering, J. C. Lynch, J. O. Armitage, R. A. Warnke, A. A. Alizadeh, et al.
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile
Blood,
April 1, 2002;
99(7):
2285 - 2290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nanjangud, P. H. Rao, A. Hegde, J. Teruya-Feldstein, G. Donnelly, J. Qin, S. C. Jhanwar, A. D. Zelenetz, and R. S. K. Chaganti
Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma
Blood,
April 1, 2002;
99(7):
2554 - 2561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ueda, T. Uchiyama, and H. Ohno
Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA
Blood,
April 1, 2002;
99(7):
2624 - 2625.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Aster and J. A. Longtine
Detection of BCL2 Rearrangements in Follicular Lymphoma
Am. J. Pathol.,
March 1, 2002;
160(3):
759 - 763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, C. D. Jones, R. Warnke, Y. Natkunam, H. Kaizer, J. L. Zehnder, R. Tibshirani, and R. Levy
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
Blood,
August 15, 2001;
98(4):
945 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Straus, E. S. Jaffe, J. M. Puck, J. K. Dale, K. B. Elkon, A. Rosen-Wolff, A. M. J. Peters, M. C. Sneller, C. W. Hallahan, J. Wang, et al.
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis
Blood,
July 1, 2001;
98(1):
194 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Braziel, D. A. Arber, M. L. Slovak, M. L. Gulley, C. Spier, C. Kjeldsberg, J. Unger, T. P. Miller, R. Tubbs, C. Leith, et al.
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features
Blood,
June 15, 2001;
97(12):
3713 - 3720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, B. K. Link, M. L. Grossbard, M. Czuczman, A. Grillo-Lopez, P. Gilman, A. Lowe, L. A. Kunkel, and R. I. Fisher
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 15, 2001;
19(2):
389 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Akasaka, C. Ueda, M. Kurata, H. Akasaka, H. Yamabe, T. Uchiyama, and H. Ohno
Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6
Blood,
October 15, 2000;
96(8):
2907 - 2909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Willis and M. J. S. Dyer
The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies
Blood,
August 1, 2000;
96(3):
808 - 822.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Akasaka, H. Akasaka, C. Ueda, N. Yonetani, Y. Maesako, A. Shimizu, H. Yamabe, S. Fukuhara, T. Uchiyama, and H. Ohno
Molecular and Clinical Features of Non-Burkitt’s, Diffuse Large-Cell Lymphoma of B-Cell Type Associated With the c-MYC/Immunoglobulin Heavy-Chain Fusion Gene
J. Clin. Oncol.,
February 1, 2000;
18(3):
510 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Lee, J.-P. Cai, V. Deyev, P. S. Gill, L. Cabral, C. Wood, R. P. Agarwal, W. Xia, L. H. Boise, E. Podack, et al.
Azidothymidine and Interferon-{{alpha}} Induce Apoptosis in Herpesvirus-associated Lymphomas
Cancer Res.,
November 1, 1999;
59(21):
5514 - 5520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
